gdc
PSSGuide_2021
Endometrial Cancer

Drugs for Endometrial (Uterine) Cancer

Find financial assistance programs available for endometrial (uterine) cancer drugs.

Jemperli (dostarlimab-gxly) Injection

Drug company: GlaxoSmithKline
844-447-5662

Jemperli is a PD-1 inhibitor used for the treatment of adults with recurrent or advanced endometrial cancer and mismatch repair-deficient (dMMR), as determined by an FDAapproved test, that has progressed during or after treatment with a platinum-containing regimen.

GSK Oncology offers 2 financial assistance programs for patients using Jemperli:

Together with GSK Oncology Commercial Co-pay Program

Eligible patients who have private insurance can pay as little as $0 for Jemperli through this program, with a maximum annual benefit of $26,000.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Jemperli for free through this program. Qualified patients must have a maximum monthly household gross income of $5,366.67 for individuals; $7,258.33 for a family of 2; $9,150.00 for a family of 3; $11,041.67 for a family of 4; and $1,891.67 for each additional person.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used, in combination with Lenvima (lenvatinib), for the treatment of patients with advanced endometrial carcinoma without microsatellite instability-high (MSI-H) abnormality or deficient-mismatch repair (dMMR), whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for a couple, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used, in combination with Keytruda, for the treatment of patients with advanced endometrial carcinoma without microsatellite instability-high (MSI-H) abnormality or mismatch repair-deficient (dMMR), whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation.

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Patient Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Table. Drugs Prescribed for Endometrial (Uterine) Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Jemperli (dostarlimab-gxly) Injection
  • Drug company
  • GSK Oncology
  • Indication
  • Treatment of adults with recurrent or advanced endometrial cancer and dMMR, as determined by an FDA-approved test, that has progressed during or after treatment with a platinum-containing regimen
  • Patient support services
  • Together with GSK Oncology Commercial Co-pay Program
    844-447-5662

    Patient Assistance Program
    844-447-5662

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment, in combination with Lenvima, of patients with advanced endometrial carcinoma without MSI-H abnormality or dMMR, whose disease progressed after systemic therapy and who are not candidates for curative surgery or radiation
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Lenvima (lenvatinib) Capsules
  • Drug company
  • Eisai
  • Indication
  • Treatment, in combination with Keytruda, of patients with advanced endometrial carcinoma without MSI-H abnormality or dMMR, whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation
  • Patient support services
  • Lenvima $0 Co-Pay Program
    866-613-4724

    Eisai Patient Assistance Program
    866-613-4724
dMMR indicates mismatch repair-deficient; MSI-H, microsatellite instability-high.

Share this:

Last modified: March 21, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest